US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US5981719A
(en)
|
1993-03-09 |
1999-11-09 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US5766629A
(en)
|
1995-08-25 |
1998-06-16 |
Sangstat Medical Corporation |
Oral cyclosporin formulations
|
US6368586B1
(en)
|
1996-01-26 |
2002-04-09 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers
|
US5985312A
(en)
*
|
1996-01-26 |
1999-11-16 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers
|
US6120806A
(en)
*
|
1997-06-25 |
2000-09-19 |
Whitmire; David R. |
Oral formulations for controlled release of alcohol deterrents
|
FR2775435B1
(fr)
*
|
1998-02-27 |
2000-05-26 |
Bioalliance Pharma |
Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US20040259895A1
(en)
*
|
1998-05-28 |
2004-12-23 |
Medical Research Institute |
Oral formulation of lipid soluble thiamine and lipoic acid
|
US6905707B2
(en)
*
|
1998-05-28 |
2005-06-14 |
Medical Research Institute |
Controlled release arginine alpha ketoglutarate
|
US20050085498A1
(en)
*
|
1998-05-28 |
2005-04-21 |
Byrd Edward A. |
Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
|
US6197340B1
(en)
*
|
1998-05-28 |
2001-03-06 |
Medical Research Institute |
Controlled release lipoic acid
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
EP1117384A1
(en)
*
|
1998-10-01 |
2001-07-25 |
Elan Pharma International Limited |
Controlled release nanoparticulate compositions
|
US6984404B1
(en)
|
1998-11-18 |
2006-01-10 |
University Of Florida Research Foundation, Inc. |
Methods for preparing coated drug particles and pharmaceutical formulations thereof
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
ATE338120T2
(de)
|
1998-11-27 |
2006-09-15 |
Ucb Sa |
Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
|
AU768535B2
(en)
|
1998-11-30 |
2003-12-18 |
Nanosphere, Inc. |
Nanoparticles with polymer shells
|
ATE276199T1
(de)
|
1999-02-03 |
2004-10-15 |
Biosante Pharmaceuticals Inc |
Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
|
US20040258763A1
(en)
*
|
1999-02-03 |
2004-12-23 |
Bell Steve J.D. |
Methods of manufacture and use of calcium phosphate particles containing allergens
|
US20020054914A1
(en)
*
|
1999-02-03 |
2002-05-09 |
Tulin Morcol |
Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
|
US6410255B1
(en)
*
|
1999-05-05 |
2002-06-25 |
Aurora Biosciences Corporation |
Optical probes and assays
|
DE60043400D1
(de)
|
1999-05-14 |
2010-01-07 |
Nereus Pharmaceuticals Inc |
Interleukin-1 und Tumornekrosefaktor-alpha Modulatoren,Synthese dieser Modulatoren und Methoden zur Anwendung dieser Modulatoren
|
EP1754488A1
(en)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
US6406745B1
(en)
*
|
1999-06-07 |
2002-06-18 |
Nanosphere, Inc. |
Methods for coating particles and particles produced thereby
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
RU2155602C1
(ru)
|
1999-11-30 |
2000-09-10 |
Оао "Куантум Сатис" |
Инсулинсодержащее лекарственное средство для перорального применения и способ его получения
|
EP1259608B1
(en)
*
|
2000-02-23 |
2009-08-12 |
Life Technologies Corporation |
Modified fluorescent proteins
|
ES2389445T3
(es)
|
2000-02-23 |
2012-10-26 |
Glaxosmithkline Biologicals Sa |
Compuestos novedosos
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
EP1272231A1
(en)
|
2000-04-06 |
2003-01-08 |
University Technology Corporation |
Compositions and methods for promoting wound healing
|
US10293056B1
(en)
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
CA2309575A1
(en)
*
|
2000-05-26 |
2001-11-26 |
James E. Guillet |
Internally cross-linked macromolecules
|
SI1542732T1
(sl)
|
2000-06-20 |
2010-01-29 |
Corixa Corp Csc The United Sta |
Fuzijski proteini Mycobacterium tuberculosis
|
AU2001273149A1
(en)
|
2000-06-28 |
2002-01-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6602523B1
(en)
|
2000-08-17 |
2003-08-05 |
Technology Holding, Llc. |
Composite material and process for increasing bioavailability and activity of a beneficial agent
|
AU4322802A
(en)
*
|
2000-11-16 |
2002-06-24 |
Univ California |
Marine actinomycete taxon for drug and fermentation product dicovery
|
AU2002220257A1
(en)
*
|
2000-12-07 |
2002-06-18 |
Board Of Regents, The University Of Texas System |
Methods of treatment involving human mda-7
|
US8067032B2
(en)
*
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US20050048126A1
(en)
*
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US7037528B2
(en)
*
|
2000-12-22 |
2006-05-02 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US20040256749A1
(en)
*
|
2000-12-22 |
2004-12-23 |
Mahesh Chaubal |
Process for production of essentially solvent-free small particles
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
US20030072807A1
(en)
*
|
2000-12-22 |
2003-04-17 |
Wong Joseph Chung-Tak |
Solid particulate antifungal compositions for pharmaceutical use
|
US6884436B2
(en)
*
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
US9700866B2
(en)
*
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
US20040022862A1
(en)
*
|
2000-12-22 |
2004-02-05 |
Kipp James E. |
Method for preparing small particles
|
CA2446788A1
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US20030185892A1
(en)
*
|
2001-08-17 |
2003-10-02 |
Bell Steve J. D. |
Intraocular delivery compositions and methods
|
WO2003024425A1
(en)
*
|
2001-09-19 |
2003-03-27 |
Elan Pharma International, Ltd. |
Nanoparticulate insulin formulations
|
AU2002337692B2
(en)
*
|
2001-09-26 |
2007-09-13 |
Baxter International Inc. |
Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
EP2224012B1
(en)
|
2001-12-17 |
2013-01-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
WO2003075952A1
(en)
*
|
2002-03-05 |
2003-09-18 |
Board Of Regents, The University Of Texas System |
Methods of enhancing immune induction involving mda-7
|
US7799523B2
(en)
|
2002-04-03 |
2010-09-21 |
Celltech R & D, Inc. |
Association of polymorphisms in the SOST gene region with bone mineral density
|
WO2003086278A2
(en)
|
2002-04-05 |
2003-10-23 |
Board Of Regents, The University Of Texas System |
Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
|
US7176232B2
(en)
|
2002-06-24 |
2007-02-13 |
The Regents Of The University Of California |
Salinosporamides and methods for use thereof
|
EP2269618A1
(en)
|
2002-08-12 |
2011-01-05 |
Jennerex Biotherapeutics ULC |
An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.
|
WO2004034970A2
(en)
*
|
2002-09-27 |
2004-04-29 |
Nereus Pharmaceuticals, Inc. |
Macrocyclic lactams
|
US20050051968A1
(en)
*
|
2002-11-13 |
2005-03-10 |
Froesel David William |
Washer toss game
|
US7824851B2
(en)
|
2002-11-15 |
2010-11-02 |
Idenix Pharmaceuticals, Inc. |
2′-branched nucleosides and Flaviviridae mutation
|
AU2003301064A1
(en)
*
|
2002-12-17 |
2004-07-14 |
Massachusetts Institute Of Technology |
Stimuli-responsive systems for controlled drug delivery
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
RU2389732C2
(ru)
|
2003-01-06 |
2010-05-20 |
Корикса Корпорейшн |
Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
|
WO2004067013A1
(en)
*
|
2003-01-24 |
2004-08-12 |
Flora Technology Inc. |
Compositions and methods for restoring bacterial flora
|
WO2004078124A2
(en)
*
|
2003-03-03 |
2004-09-16 |
Board Of Regents, The University Of Texas System |
Methods and compositions involving mda-7
|
US7381409B2
(en)
|
2003-06-16 |
2008-06-03 |
Celltech R&D, Inc. |
Antibodies specific for sclerostin and methods of screening and use therefor
|
CN101791306A
(zh)
*
|
2003-06-20 |
2010-08-04 |
加利福尼亚大学董事会 |
盐孢菌酰胺及其使用方法
|
CA2532066C
(en)
*
|
2003-06-20 |
2015-07-28 |
Nereus Pharmaceuticals, Inc. |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof
|
JP4951338B2
(ja)
|
2003-07-16 |
2012-06-13 |
プロチバ バイオセラピューティクス インコーポレイティッド |
脂質に封入された干渉rna
|
US7727752B2
(en)
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
EP1525890A1
(en)
*
|
2003-10-02 |
2005-04-27 |
Complex Biosystems GmbH |
Protein-Proteophore complexes
|
EP1684580A2
(en)
|
2003-10-22 |
2006-08-02 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and devices for inducing stasis in tissues and organs
|
US8034790B2
(en)
*
|
2003-12-01 |
2011-10-11 |
Introgen Therapeutics |
Use of MDA-7 to inhibit pathogenic infectious organisms
|
JP2007519727A
(ja)
*
|
2004-01-23 |
2007-07-19 |
ネレアス ファーマシューティカルズ インコーポレイテッド |
抗菌薬として有用なビス−インドールピロール
|
CA2555921A1
(en)
*
|
2004-02-13 |
2005-09-15 |
Nod Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles and methods of making and using same
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
US7579371B2
(en)
|
2004-04-30 |
2009-08-25 |
Nereus Pharmaceuticals, Inc. |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof
|
WO2006028525A2
(en)
*
|
2004-04-30 |
2006-03-16 |
Nereus Pharmaceuticals, Inc. |
[3.2.0] heterocyclic compounds and methods of using the same
|
WO2006031264A2
(en)
|
2004-05-25 |
2006-03-23 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
|
US20080280973A1
(en)
*
|
2004-06-28 |
2008-11-13 |
Wender Paul A |
Laulimalide Analogues as Therapeutic Agents
|
FR2872703B1
(fr)
*
|
2004-07-07 |
2006-10-06 |
Ethypharm Sa |
Nanoparticules polymeriques composites
|
CN1732962A
(zh)
*
|
2004-08-11 |
2006-02-15 |
张阳德 |
阿霉素-聚氰基丙烯酸正丁脂纳米粒的制备方法
|
CN1733313A
(zh)
*
|
2004-08-11 |
2006-02-15 |
张阳德 |
聚氰基丙烯酸正丁酯纳米颗粒的制备方法
|
EP1781257B1
(en)
*
|
2004-08-13 |
2018-12-19 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
EP1799227B1
(en)
|
2004-09-18 |
2010-11-10 |
University of Maryland, Baltimore |
Therapeutic agents targeting the nc ca-atp channel and methods of use thereof
|
CN101043891A
(zh)
|
2004-09-18 |
2007-09-26 |
巴尔的摩马里兰大学 |
靶向NCCa-ATP通道的治疗剂及其使用方法
|
US7282194B2
(en)
*
|
2004-10-05 |
2007-10-16 |
Gp Medical, Inc. |
Nanoparticles for protein drug delivery
|
CA2586035A1
(en)
|
2004-11-01 |
2006-05-11 |
Biosante Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles in use for aesthetic or cosmetic medicine, and methods of manufacture and use
|
CN101155582B
(zh)
*
|
2004-12-03 |
2013-04-24 |
达纳-法伯癌症研究公司 |
治疗肿瘤性疾病的组合物和方法
|
DK1885746T3
(da)
|
2005-02-08 |
2012-03-26 |
Res Dev Foundation |
Sammensætninger relateret til opløselige G-protein-koblede receptorer (sGPCRs)
|
EP1863516A2
(en)
*
|
2005-02-08 |
2007-12-12 |
Board of Regents, The University of Texas System |
Compositions and methods involving mda-7 for the treatment of cancer
|
ES2259914B1
(es)
*
|
2005-03-14 |
2007-06-16 |
Advanced In Vitro Cell Technologies, S.L. |
Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas.
|
UA97943C2
(ru)
|
2005-03-31 |
2012-04-10 |
ГлаксоСмитКлайн Байолоджикалз с.а. |
Вакцина против инфекции chlamydia
|
DK1883665T3
(da)
|
2005-04-22 |
2017-11-13 |
Univ Geneve |
Polylactidsammensætninger og anvendelser deraf
|
ITMI20050739A1
(it)
*
|
2005-04-22 |
2006-10-23 |
Effebi Spa |
Piastrina di connsessione valvola-attuatore
|
DK2457926T3
(da)
|
2005-04-29 |
2015-01-05 |
Glaxosmithkline Biolog Sa |
Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
US20060280787A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Baxter International Inc. |
Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
|
WO2006138202A2
(en)
*
|
2005-06-14 |
2006-12-28 |
Baxter International Inc. |
Pharmaceutical formulations for minimizing drug-drug interactions
|
US7893299B2
(en)
|
2005-07-21 |
2011-02-22 |
Nereus Pharmaceuticals, Inc. |
Interleukin-1 and tumor necrosis factor-αmodulators; syntheses of such modulators and methods of using such modulators
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
US20090156480A1
(en)
*
|
2005-08-25 |
2009-06-18 |
Mitsuru Akashi |
Biodegradable nanoparticle having t-cell recognizable epitope peptide immobilized thereon or encapsulated therein
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
KR20090004839A
(ko)
*
|
2005-09-07 |
2009-01-12 |
제네렉스, 인코포레이티드 |
Gm-csf를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
|
WO2007051303A1
(en)
|
2005-11-02 |
2007-05-10 |
Protiva Biotherapeutics, Inc. |
MODIFIED siRNA MOLECULES AND USES THEREOF
|
US20070134341A1
(en)
*
|
2005-11-15 |
2007-06-14 |
Kipp James E |
Compositions of lipoxygenase inhibitors
|
WO2007062399A2
(en)
|
2005-11-23 |
2007-05-31 |
The Board Of Regents Of The University Of Texas System |
Oncogenic ras-specific cytotoxic compound and methods of use thereof
|
EP1954670A4
(en)
|
2005-11-28 |
2011-04-27 |
Gtx Inc |
NUCLEAR RECEPTOR BINDING AGENTS
|
AU2007239095B2
(en)
|
2006-01-09 |
2012-05-03 |
The Regents Of The University Of California |
Immunostimulatory combinations for vaccine adjuvants
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
EP1876188A1
(en)
*
|
2006-07-04 |
2008-01-09 |
NanoDel Technologies GmbH |
Two step miniemulsion process
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
US8080645B2
(en)
*
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US8652782B2
(en)
|
2006-09-12 |
2014-02-18 |
Longhorn Vaccines & Diagnostics, Llc |
Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
|
EP2839837B1
(en)
|
2006-09-15 |
2019-05-08 |
Children's Hospital of Eastern Ontario Research Institute Inc. |
Oncolytic farmington rhabdovirus
|
CA2663962A1
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
US8466154B2
(en)
|
2006-10-27 |
2013-06-18 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to wrapping of dehydrons
|
EP2094731A2
(en)
*
|
2006-11-10 |
2009-09-02 |
UCB Pharma S.A. |
Anti human sclerostin antibodies
|
WO2008061013A2
(en)
*
|
2006-11-10 |
2008-05-22 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
AU2007353332B2
(en)
|
2006-11-21 |
2013-08-01 |
The Regents Of The University Of California |
Modulation of Rhamm (CD168) for selective adipose tissue development
|
US20080138418A1
(en)
*
|
2006-12-07 |
2008-06-12 |
Tong Shen Enterprise Co., Ltd. |
Nanoparticles composed of alkyl-cyanoacrylate polymers
|
CA2674949A1
(en)
|
2007-01-12 |
2008-07-24 |
J. Marc Simard |
Targeting ncca-atp channel for organ protection following ischemic episode
|
US8679539B2
(en)
*
|
2007-01-31 |
2014-03-25 |
Tong Shen Enterprise Co., Ltd. |
Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
|
EP2120580B1
(en)
|
2007-02-02 |
2017-12-27 |
Baylor College Of Medicine |
Compositions and methods for the treatment of metabolic disorders
|
US7824698B2
(en)
*
|
2007-02-02 |
2010-11-02 |
Nereus Pharmaceuticals, Inc. |
Lyophilized formulations of Salinosporamide A
|
EP2114160B1
(en)
|
2007-02-09 |
2016-11-16 |
University of Maryland, Baltimore |
Antagonists of a non-selective cation channel in neural cells
|
KR20080084528A
(ko)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
EP3199176B1
(en)
|
2007-04-04 |
2020-02-19 |
Infectious Disease Research Institute |
Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
EP3492596A1
(en)
|
2007-04-09 |
2019-06-05 |
University of Florida Research Foundation, Inc. |
Raav vector compositions having tyrosine-modified capsid proteins and methods for use
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
CN101742906A
(zh)
|
2007-06-04 |
2010-06-16 |
本古里安大学内盖夫研究发展局 |
三芳基化合物和包含它们的组合物
|
CA3065983C
(en)
|
2007-06-22 |
2022-07-26 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Inhibitors of ncca-atp channels for therapy
|
US20090017167A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Herbalife International Inc. |
Mixture and beverage made therefrom for protecting cellular hydration
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
CA2697373C
(en)
|
2007-08-27 |
2019-05-21 |
Longhorn Vaccines & Diagnostics, Llc |
Immunogenic compositions and methods
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
ES2552858T3
(es)
|
2007-10-01 |
2015-12-02 |
Longhorn Vaccines And Diagnostics, Llc |
Recogida de muestras biológicas y sistema de transporte y métodos de uso
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
US8394816B2
(en)
*
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
EP2628486A3
(en)
|
2007-12-14 |
2013-10-30 |
Amgen, Inc. |
Method for treating bone fracture with anti-sclerostin antibodies
|
EP2236143A4
(en)
*
|
2007-12-27 |
2011-01-05 |
Public Univ Corp Yokohama City |
ANTIMICROBIOTICS FOR GRAM-POSITIVE BACTERIA
|
CA2710713C
(en)
|
2007-12-27 |
2017-09-19 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
AU2009236219B8
(en)
|
2008-04-15 |
2015-06-25 |
Arbutus Biopharma Corporation |
Silencing of CSN5 gene expression using interfering RNA
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
EP2285960B1
(en)
|
2008-05-08 |
2015-07-08 |
Asuragen, INC. |
Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis
|
CA2723563C
(en)
*
|
2008-05-09 |
2017-12-12 |
South Dakota State University |
Method of forming non-immunogenic hydrophobic protein nanoparticles, and uses therefor
|
CA2723465A1
(en)
*
|
2008-05-12 |
2009-11-19 |
Nereus Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US8404471B2
(en)
|
2008-06-26 |
2013-03-26 |
Atyr Pharma, Inc. |
Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities
|
EP2326318A4
(en)
|
2008-09-16 |
2012-05-23 |
Univ Maryland |
SUR1 HEMMER FOR THERAPEUTIC PURPOSES
|
US8349899B1
(en)
|
2008-12-03 |
2013-01-08 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
US8765817B1
(en)
|
2008-12-03 |
2014-07-01 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
EP2403864B1
(en)
|
2009-02-27 |
2015-08-12 |
Atyr Pharma, Inc. |
Polypeptide structural motifs associated with cell signaling activity
|
WO2010107825A2
(en)
|
2009-03-16 |
2010-09-23 |
Pangu Biopharma Limited |
Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
|
AU2010236913B2
(en)
|
2009-03-31 |
2016-03-24 |
Atyr Pharma, Inc. |
Compositions and methods comprising aspartyl-tRNA synthetases having non-canonical biological activities
|
JP2012524818A
(ja)
|
2009-04-24 |
2012-10-18 |
バンダービルト ユニバーシティ |
骨細胞機能および骨成長の抗TGF−βによる誘導法
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
DK2456304T3
(en)
|
2009-07-24 |
2015-08-31 |
Baylor College Medicine |
METHODS OF MODULATING acids with branched chains and uses thereof
|
ES2545794T3
(es)
|
2009-08-28 |
2015-09-15 |
Research Development Foundation |
Análogos de urocortina 2 y usos de los mismos
|
BR112012005774B8
(pt)
|
2009-09-14 |
2023-02-14 |
Jennerex Inc |
uso de um inibidor de quinase antiangiogênico no tratamento de câncer
|
EP2480668A2
(en)
|
2009-09-23 |
2012-08-01 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing genes expressed in cancer
|
MX337062B
(es)
|
2009-12-10 |
2016-02-11 |
Ottawa Hospital Res Inst |
Rabdovirus oncolítico.
|
WO2011072266A2
(en)
|
2009-12-11 |
2011-06-16 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
US9127268B2
(en)
|
2009-12-11 |
2015-09-08 |
Atyr Pharma, Inc. |
Aminoacyl tRNA synthetases for modulating inflammation
|
EP2512600A2
(en)
|
2009-12-18 |
2012-10-24 |
Amgen Inc. |
Wise binding agents and epitopes
|
MX2012008790A
(es)
|
2010-01-27 |
2012-08-17 |
Glaxosmithkline Biolog Sa |
Antigenos de tuberculosis modificados.
|
EP2826860B1
(en)
|
2010-04-23 |
2018-08-22 |
University of Massachusetts |
CNS targeting AAV vectors and methods of use thereof
|
KR20190060881A
(ko)
|
2010-04-23 |
2019-06-03 |
유니버시티 오브 플로리다 리서치 파운데이션, 인크. |
레베르 선천성 흑내장-1(lca1)의 치료를 위한 재조합 아데노-관련된 바이러스-구아닐레이트 사이클라제 조성물 및 방법
|
WO2011133980A1
(en)
|
2010-04-23 |
2011-10-27 |
Subhash Desai |
Therapeutic formulation for reduced drug side effects
|
WO2011133901A2
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
WO2011139714A2
(en)
|
2010-04-26 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
|
EP2563381B1
(en)
|
2010-04-27 |
2017-08-09 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
|
EP2563911B1
(en)
|
2010-04-28 |
2021-07-21 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
|
US9034320B2
(en)
|
2010-04-29 |
2015-05-19 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
|
AU2011248490B2
(en)
|
2010-04-29 |
2016-11-10 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
|
CA2797277C
(en)
|
2010-05-03 |
2021-02-23 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
|
EP2566495B1
(en)
|
2010-05-03 |
2017-03-01 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
|
EP2566496B1
(en)
|
2010-05-03 |
2018-02-28 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
AU2011248101B2
(en)
|
2010-05-04 |
2016-10-20 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
|
US10077232B2
(en)
|
2010-05-12 |
2018-09-18 |
Arbutus Biopharma Corporation |
Cyclic cationic lipids and methods of use
|
EP2569276B1
(en)
|
2010-05-12 |
2021-02-24 |
Arbutus Biopharma Corporation |
Novel cationic lipids and methods of use thereof
|
EP2569010B1
(en)
|
2010-05-14 |
2017-04-12 |
Amgen, Inc |
High concentration antibody formulations
|
AU2011252990B2
(en)
|
2010-05-14 |
2017-04-20 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
AU2011256366C1
(en)
|
2010-05-17 |
2017-06-15 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
|
JP6046607B2
(ja)
|
2010-05-27 |
2016-12-21 |
エータイアー ファーマ, インコーポレイテッド |
グルタミニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
CA2800281C
(en)
|
2010-06-01 |
2021-01-12 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
|
JP6116479B2
(ja)
|
2010-07-12 |
2017-04-19 |
エータイアー ファーマ, インコーポレイテッド |
グリシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
EP4050109A1
(en)
|
2010-08-18 |
2022-08-31 |
Fred Hutchinson Cancer Center |
Agents for use in treating facioscapulohumeral dystrophy (fshd)
|
US9029506B2
(en)
|
2010-08-25 |
2015-05-12 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
WO2012064659A1
(en)
|
2010-11-08 |
2012-05-18 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
CN103429258B
(zh)
|
2011-01-04 |
2016-03-09 |
新罗杰公司 |
通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性
|
BR112013017711A2
(pt)
|
2011-01-11 |
2016-08-23 |
Fate Therapeutics Inc |
novas composições de wnt e usos terapêuticos de tais composições
|
WO2012103328A1
(en)
|
2011-01-26 |
2012-08-02 |
The Methodist Hospital Research Institute |
Labeled, non- peptidic multivalent integrin alpha -v - beta - 3 antagonists, compositions containing them and their use
|
WO2012106591A1
(en)
|
2011-02-03 |
2012-08-09 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-34
|
WO2012106586A1
(en)
|
2011-02-03 |
2012-08-09 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-124
|
US8986739B2
(en)
|
2011-02-28 |
2015-03-24 |
Nicholas V. Perricone |
Treatment of urinary incontinence using nitrone spin traps
|
CN103649118A
(zh)
|
2011-03-01 |
2014-03-19 |
安进公司 |
双特异性结合剂
|
SG193610A1
(en)
|
2011-03-25 |
2013-11-29 |
Amgen Inc |
Anti - sclerostin antibody crystals and formulations thereof
|
WO2012133648A1
(ja)
|
2011-03-31 |
2012-10-04 |
Shirotake Shoichi |
高次構造体が示す抗細胞効果の新規調整技法
|
DK3404041T3
(da)
|
2011-04-19 |
2020-08-24 |
Amgen Inc |
Fremgangsmåde til behandling af osteoporose
|
CA2872045A1
(en)
|
2011-06-08 |
2012-12-13 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions and methods for glioblastoma treatment
|
US9789139B2
(en)
|
2011-06-10 |
2017-10-17 |
Bluebird Bio, Inc. |
Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
|
CN103608030A
(zh)
|
2011-06-21 |
2014-02-26 |
昂科发克特公司 |
用于治疗和诊断癌症的组合物和方法
|
PL2734634T3
(pl)
|
2011-07-22 |
2020-03-31 |
The University Of Chicago |
Igf-1 do zastosowania do leczenia migreny
|
HUE039786T2
(hu)
|
2011-08-04 |
2019-02-28 |
Amgen Inc |
Csonthiány-defektusok kezelési módszere
|
US9655905B2
(en)
|
2011-09-14 |
2017-05-23 |
King Abdullah University Of Science And Technology |
Treatment of sickle cell disease
|
WO2013041969A2
(en)
|
2011-09-21 |
2013-03-28 |
King Abdullah University Of Science And Technology |
Didemnin biosynthetic gene cluster in tistrella mobilis
|
AU2011377617B2
(en)
|
2011-09-23 |
2018-03-08 |
Bluebird Bio, Inc. |
Improved gene therapy methods
|
WO2013095736A2
(en)
|
2011-09-27 |
2013-06-27 |
The Methodist Hospital Research Institute |
Gold-in-silicon nanoassembly for thermal therapy and methods of use
|
JP6285863B2
(ja)
|
2011-09-30 |
2018-02-28 |
ブルーバード バイオ, インコーポレイテッド |
改善されたウイルスによる形質導入のための化合物
|
EP2768481A4
(en)
|
2011-10-21 |
2015-07-08 |
Subhash Desai |
COMPOSITIONS TO REDUCE SIDE EFFECTS
|
WO2013151584A1
(en)
|
2011-10-31 |
2013-10-10 |
The Methodist Hospital Research Institute |
Compound comprising a mao targeting/ seeker moiety for treating human gliomas
|
CN104080797A
(zh)
|
2011-11-11 |
2014-10-01 |
弗雷德哈钦森癌症研究中心 |
针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
|
CA2856722C
(en)
|
2011-11-30 |
2022-11-22 |
Emory University |
Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
|
WO2013086433A1
(en)
|
2011-12-07 |
2013-06-13 |
The Methodist Hospital Research Institute |
Sirna compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
KR20190120401A
(ko)
|
2011-12-28 |
2019-10-23 |
암젠 인크 |
항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
|
US20150004202A1
(en)
|
2012-01-19 |
2015-01-01 |
Shoichi Shirotake |
Antibacterial agent against plant disease-causing bacteria
|
CN104203272A
(zh)
|
2012-01-26 |
2014-12-10 |
长角牛疫苗和诊断有限责任公司 |
复合抗原序列及疫苗
|
EP2852413A4
(en)
|
2012-02-16 |
2016-04-27 |
Univ Toledo |
XENOANTIGEN WITH VACCINES AGAINST CANCER AND MANUFACTURING PROCESS THEREFOR
|
KR102075810B1
(ko)
|
2012-02-24 |
2020-02-10 |
아뷰터스 바이오파마 코포레이션 |
트리알킬 양이온성 지질 및 그의 사용 방법
|
AR092821A1
(es)
|
2012-04-20 |
2015-05-06 |
Sucampo Ag |
Conjugado de derivado de acido graso-polimero
|
IN2014DN09297A
(pt)
*
|
2012-05-16 |
2015-07-10 |
Glaxo Group Ltd |
|
JP6228191B2
(ja)
|
2012-05-23 |
2017-11-08 |
ジ・オハイオ・ステート・ユニバーシティ |
脂質コートされたアルブミンナノ粒子組成物と、それを作製する方法、及びそれを使用する方法
|
EP2869844B2
(en)
|
2012-07-05 |
2023-06-21 |
UCB Pharma S.A. |
Treatment for bone diseases
|
HUE065746T2
(hu)
|
2012-08-03 |
2024-06-28 |
Access To Advanced Health Inst |
Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére
|
EP2931300A1
(en)
*
|
2012-08-14 |
2015-10-21 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
EP2934562A1
(en)
*
|
2012-08-14 |
2015-10-28 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
EP3985024A1
(en)
|
2013-02-01 |
2022-04-20 |
Atara Biotherapeutics, Inc. |
Anti-activin-a compounds for the treatment of ovarian cancer
|
CA2901501C
(en)
|
2013-02-21 |
2023-03-07 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Vaccine composition
|
WO2014160339A1
(en)
|
2013-03-13 |
2014-10-02 |
Board Of Regents, The University Of Texas System |
Compounds for treating inflammatory and hyperproliferative diseases
|
US9909114B2
(en)
|
2013-03-28 |
2018-03-06 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
WO2014186746A1
(en)
|
2013-05-16 |
2014-11-20 |
University Of Florida Research Foundation, Inc. |
HAIRPIN mRNA ELEMENTS AND METHODS FOR THE REGULATION OF PROTEIN TRANSLATION
|
EP3677567A1
(en)
|
2013-07-23 |
2020-07-08 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger rna
|
JP6657101B2
(ja)
|
2013-11-05 |
2020-03-04 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
糖尿病及びそれから生じる疾患合併症の治療のための化合物
|
JP6667437B2
(ja)
|
2013-12-02 |
2020-03-18 |
ベイラー カレッジ オブ メディスンBaylor College Of Medicine |
最適な体重及び血糖を維持するための新規ポリペプチドホルモンの同定
|
JP6533213B2
(ja)
|
2014-02-27 |
2019-06-19 |
昇一 城武 |
抗ウイルス剤
|
CN111620830A
(zh)
|
2014-03-14 |
2020-09-04 |
北卡罗来纳大学教堂山分校 |
用于抑制雄性生育力的小分子
|
WO2015157471A1
(en)
|
2014-04-08 |
2015-10-15 |
The Methodist Hospital |
Inos-inhibitory compositions and their use as breast cancer therapeutics
|
WO2015157500A1
(en)
|
2014-04-09 |
2015-10-15 |
Research Development Foundation |
Class iia hdac inhibitors for the treatment of infection
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
JP6910800B2
(ja)
|
2014-06-20 |
2021-07-28 |
アベオ ファーマシューティカルズ, インコーポレイテッド |
Gdf15調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
|
US20170137506A1
(en)
|
2014-06-20 |
2017-05-18 |
Aveo Pharmaceuticals, Inc. |
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
|
WO2016025202A1
(en)
|
2014-08-14 |
2016-02-18 |
The Regents Of The University Of Colorado |
Antibody-sirna conjugates and uses therefor
|
TWI691597B
(zh)
|
2014-09-01 |
2020-04-21 |
中央研究院 |
延長壽命與抑制腫瘤發生的動物模型
|
AU2015312134A1
(en)
|
2014-09-02 |
2017-03-23 |
Bhupinder Singh |
Deuterated or a non-deuterated molecule and pharmaceutical formulations
|
EP3620521B1
(en)
|
2014-09-04 |
2024-05-29 |
Memorial Sloan-Kettering Cancer Center |
Globin gene therapy for treating hemoglobinopathies
|
EP3197493B1
(en)
|
2014-09-25 |
2021-03-10 |
Aveo Pharmaceuticals Inc. |
Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
|
SG11201702662UA
(en)
|
2014-10-02 |
2017-04-27 |
Protiva Biotherapeutics Inc |
Compositions and methods for silencing hepatitis b virus gene expression
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
WO2016057563A1
(en)
|
2014-10-08 |
2016-04-14 |
Pacific Northwest Diabetes Research Institute |
Methods and compositions for increasing the potency of antifungal agents
|
BR112017007737A2
(pt)
|
2014-10-21 |
2018-01-30 |
Univ Massachusetts |
variantes de aav recombinantes e usos das mesmas
|
US10302644B2
(en)
|
2014-11-04 |
2019-05-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating multiple myeloma
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
CA2967468A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
ES2836258T3
(es)
|
2015-03-10 |
2021-06-24 |
Univ Columbia |
Construcciones de vectores virales adenoasociados de GLUT1 recombinante y métodos relacionados para restaurar la expresión de GLUT1
|
US11285190B2
(en)
|
2015-04-20 |
2022-03-29 |
The Board Of Regents Of The University Of Texas System |
CLEC11a is a bone growth agent
|
EP3285788A4
(en)
|
2015-04-23 |
2018-12-05 |
University of Massachusetts |
Modulation of aav vector transgene expression
|
US9976136B2
(en)
|
2015-05-14 |
2018-05-22 |
Longhorn Vaccines And Diagnostics, Llc |
Rapid methods for the extraction of nucleic acids from biological samples
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
WO2016205615A1
(en)
|
2015-06-17 |
2016-12-22 |
The Johns Hopkins University |
Tdp-43 in degenerative disease
|
WO2017019891A2
(en)
|
2015-07-29 |
2017-02-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing hepatitis b virus gene expression
|
US20170056485A1
(en)
|
2015-08-31 |
2017-03-02 |
Sciotec Diagnostic Technologies Gmbh |
Crystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease
|
US11253576B2
(en)
|
2015-10-22 |
2022-02-22 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
JP2018532810A
(ja)
|
2015-11-07 |
2018-11-08 |
マルチビア インコーポレイテッド |
がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物
|
DK3408382T3
(da)
|
2016-01-27 |
2022-06-20 |
Oncorus Inc |
Onkolytiske virale vektorer og anvendelser deraf
|
US10695322B2
(en)
|
2016-01-29 |
2020-06-30 |
The Johns Hopkins University |
Inhibitors of bacterial growth
|
EP4094780A3
(en)
|
2016-02-12 |
2023-02-08 |
University of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
WO2017143112A2
(en)
|
2016-02-17 |
2017-08-24 |
The Johns Hopkins University |
An oxazolidinone for treatment of infections with mycobacterium tuberculosis
|
WO2017143286A1
(en)
*
|
2016-02-19 |
2017-08-24 |
Wilfred Chen |
Functionalized nanoparticles for enhanced affinity precipitation of proteins
|
WO2017147215A1
(en)
|
2016-02-22 |
2017-08-31 |
The Methodist Hospital |
Biomimetic proteolipid vesicle compositions and uses thereof
|
WO2017147370A1
(en)
|
2016-02-24 |
2017-08-31 |
The Johns Hopkins University |
Novel antiviral proteins and their uses in therapeutic methods
|
KR20180114946A
(ko)
|
2016-03-02 |
2018-10-19 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
면역요법을 위한 sting 활성화 나노백신
|
AU2017228413A1
(en)
|
2016-03-03 |
2018-08-23 |
University Of Massachusetts |
Closed-ended linear duplex DNA for non-viral gene transfer
|
US10888549B2
(en)
|
2016-03-07 |
2021-01-12 |
The Johns Hopkins University |
Pharmaceutical agents targeting cancer stem cells
|
US11203626B2
(en)
|
2016-03-10 |
2021-12-21 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
US11965009B2
(en)
|
2016-03-10 |
2024-04-23 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
CN109790545A
(zh)
|
2016-03-10 |
2019-05-21 |
约翰·霍普金斯大学 |
产生不含聚集物的单体白喉毒素融合蛋白的方法和治疗用途
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
CN109414417A
(zh)
|
2016-03-17 |
2019-03-01 |
约翰·霍普金斯大学 |
通过paris的法尼基化预防或治疗帕金森症的方法
|
EP3436609B1
(en)
|
2016-03-30 |
2022-05-04 |
The Johns Hopkins University |
Olfr90 specificity and methods of detection
|
US11016085B2
(en)
|
2016-04-25 |
2021-05-25 |
The Johns Hopkins University |
ZNT8 assays for drug development and pharmaceutical compositions
|
MX2018014270A
(es)
|
2016-05-21 |
2019-02-14 |
Infectious Disease Res Inst |
Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
|
CN109563511A
(zh)
|
2016-06-30 |
2019-04-02 |
阿布特斯生物制药公司 |
用于递送信使rna的组合物和方法
|
JP7493334B2
(ja)
|
2016-07-05 |
2024-05-31 |
ユニバーシティ オブ マサチューセッツ |
緑内障における神経保護療法としてのsFasLのAAV2媒介遺伝子送達
|
CA3070146A1
(en)
|
2016-07-19 |
2018-01-25 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Oncolytic viruses targeting stat3
|
WO2018035429A1
(en)
|
2016-08-18 |
2018-02-22 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r
|
CA3036218A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
US11149275B2
(en)
|
2016-10-10 |
2021-10-19 |
The Johns Hopkins University |
Device and method to treat esophageal disorders
|
US11491114B2
(en)
|
2016-10-12 |
2022-11-08 |
Curioralrx, Llc |
Formulations for enteric delivery of therapeutic agents
|
KR20190075964A
(ko)
|
2016-10-13 |
2019-07-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 설계
|
JP2020510624A
(ja)
|
2016-12-12 |
2020-04-09 |
マルチビア インコーポレイテッド |
がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
|
US10434089B2
(en)
|
2017-01-25 |
2019-10-08 |
The Johns Hopkins University |
Avibactam and carbapenems antibacterial agents
|
EP4309739A3
(en)
|
2017-01-27 |
2024-04-17 |
The Methodist Hospital |
Core/shell structure platform for immunotherapy
|
WO2018146689A1
(en)
|
2017-02-12 |
2018-08-16 |
Ben-Gurion University Of The Negev Research And Development Authority |
Telomerase activating compounds for use in fertility and related applications
|
US20210139932A1
(en)
|
2017-05-03 |
2021-05-13 |
Biomarin Pharmaceutical Inc. |
Improved lentiviruses for transduction of hematopoietic stem cells
|
EA201992882A1
(ru)
|
2017-06-06 |
2020-05-25 |
Юниверсити Оф Массачусеттс |
САМОРЕГУЛИРУЕМЫЕ ВЕКТОРЫ НА ОСНОВЕ AAV ДЛЯ БЕЗОПАСНОЙ ЭКСПРЕССИИ MeCP2 ПРИ СИНДРОМЕ PETTA
|
CN111316099A
(zh)
|
2017-07-12 |
2020-06-19 |
约翰霍普金斯大学 |
用于1型糖尿病诊断的基于脂蛋白体的znt8自身抗原
|
RU2771110C2
(ru)
|
2017-07-26 |
2022-04-26 |
Онкорус, Инк. |
Онколитические вирусные векторы и их применение
|
WO2019028469A1
(en)
|
2017-08-04 |
2019-02-07 |
The Methodist Hospital |
FUNCTIONALIZED POLYMER MITOCHONDRIAL COMPOSITIONS AND METHODS OF USE IN CELL TRANSPLANTATION AND FOR MODIFYING METABOLIC PHENOTYPE
|
AU2018330165A1
(en)
|
2017-09-08 |
2020-04-02 |
Access To Advanced Health Institute |
Liposomal formulations comprising saponin and methods of use
|
EP3710029A4
(en)
|
2017-11-16 |
2021-08-18 |
University of Maine System Board of Trustees |
COMPOSITIONS AND METHODS FOR MODULATING MIGRATION AND ANGIOGENESIS OF ENDOTHELIAL CELLS
|
WO2019113321A1
(en)
|
2017-12-06 |
2019-06-13 |
Memorial Sloan-Kettering Cancer Center |
Globin gene therapy for treating hemoglobinopathies
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
WO2019118527A1
(en)
|
2017-12-14 |
2019-06-20 |
The Johns Hopkins University |
Novel anti-fungal inhibitors
|
BR112020013715A2
(pt)
|
2018-01-05 |
2020-12-01 |
Ottawa Hospital Research Institute |
vetores de vaccinia modificados
|
AU2019322487B2
(en)
|
2018-03-19 |
2024-04-18 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
WO2019183605A1
(en)
|
2018-03-23 |
2019-09-26 |
University Of Massachusetts |
Gene therapeutics for treating bone disorders
|
MX2020010036A
(es)
|
2018-03-28 |
2021-03-02 |
Herbalife Int Of America Inc |
Acetilacion de polisacaridos.
|
WO2019191534A1
(en)
|
2018-03-30 |
2019-10-03 |
Amgen Inc. |
C-terminal antibody variants
|
US12054724B2
(en)
|
2018-04-10 |
2024-08-06 |
President And Fellows Of Harvard College |
AAV vectors encoding clarin-1 or GJB2 and uses thereof
|
WO2019210269A1
(en)
|
2018-04-27 |
2019-10-31 |
University Of Massachusetts |
Aav capsids identified by in vivo library selection
|
SG11202009914SA
(en)
|
2018-05-08 |
2020-11-27 |
Rutgers The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
KR102167755B1
(ko)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
|
CN113164625A
(zh)
|
2018-09-28 |
2021-07-23 |
哈佛大学的校长及成员们 |
用于基因表达的突变体反向四环素反式激活因子
|
AU2019347666A1
(en)
|
2018-09-28 |
2021-03-25 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
EP3887522A1
(en)
|
2018-11-29 |
2021-10-06 |
University of Massachusetts |
Modulation of sptlc1 via recombinant adeno-associated vectors
|
CN113557035A
(zh)
|
2019-01-12 |
2021-10-26 |
卫理公会医院 |
自组装肽纳米颗粒和其用途
|
WO2020163766A1
(en)
|
2019-02-07 |
2020-08-13 |
Baylor College Of Medicine |
Periosteal skeletal stem cells in bone repair
|
CA3131023A1
(en)
|
2019-02-22 |
2020-08-27 |
Michael R. Volkert |
Oxr1 gene therapy
|
US11717506B2
(en)
|
2019-05-07 |
2023-08-08 |
The Johns Hopkins University |
Neuroprotective compounds for amyotrophic lateral sclerosis
|
JP2022547305A
(ja)
|
2019-09-13 |
2022-11-11 |
ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー |
Aav適合性ラミニン-リンカー重合タンパク質
|
CN114765990A
(zh)
|
2019-10-10 |
2022-07-19 |
昂克诺斯公司 |
双重病毒和双重溶瘤病毒以及治疗方法
|
WO2021076656A1
(en)
|
2019-10-15 |
2021-04-22 |
University Of Massachusetts |
Rna editor-enhanced rna trans-splicing
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
JP2023512071A
(ja)
|
2020-01-30 |
2023-03-23 |
ウモジャ バイオファーマ, インコーポレイテッド |
二特異性形質導入エンハンサー
|
WO2021202494A1
(en)
|
2020-03-31 |
2021-10-07 |
University Of Massachusetts |
Aav capsids variants and uses thereof
|
US11965162B2
(en)
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
WO2022031359A1
(en)
|
2020-08-07 |
2022-02-10 |
Infectious Disease Research Institute |
Purified saponins and chromatographic process for purification of same
|
WO2022120080A1
(en)
|
2020-12-03 |
2022-06-09 |
University Of Massachusetts |
Development of novel gene therapeutics for fibrodysplasia ossificans progressiva
|
KR20220082558A
(ko)
|
2020-12-10 |
2022-06-17 |
재단법인 의약바이오컨버젼스연구단 |
면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도
|
MX2023008831A
(es)
|
2021-01-27 |
2023-10-19 |
Umoja Biopharma Inc |
Lentivirus para generar células que expresan receptores de antígeno quimérico anti-cd19.
|
AU2022391744A1
(en)
|
2021-11-18 |
2024-06-27 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
GB2614309A
(en)
|
2021-12-24 |
2023-07-05 |
Stratosvir Ltd |
Improved vaccinia virus vectors
|
AU2023210838A1
(en)
|
2022-01-28 |
2024-08-01 |
Fundació Centre De Regulació Genòmica |
Therapeutic cytokines and methods
|
AU2023214198A1
(en)
|
2022-01-31 |
2024-08-15 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
AU2023211981A1
(en)
|
2022-01-31 |
2024-08-15 |
Genevant Sciences Gmbh |
Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
|
WO2023196851A1
(en)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Reversing aging of the central nervous system
|
WO2023215481A1
(en)
|
2022-05-05 |
2023-11-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
INTERFERING RNA THERAPY FOR PLN-R14del CARDIOMYOPATHY
|
WO2023225569A1
(en)
|
2022-05-17 |
2023-11-23 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
WO2024097992A2
(en)
|
2022-11-04 |
2024-05-10 |
Umoja Biopharma, Inc. |
Particles displaying adhesion-molecule fusions
|
WO2024130212A1
(en)
|
2022-12-16 |
2024-06-20 |
Turnstone Biologics Corp. |
Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
|